BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Franck Bourdeaut

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: MD PhD, pediatric oncologist

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Medical school (Nantes University, France)	-	31/10/1998	Medicine
Internship in pediatrics, Paris 5-University	MD	31/05/2004	Pediatrics
Specialized in pediatric oncology, Institute Curie	-	31/10/2007	Pediatric Oncology
Master in Fundamental basis of oncology, Paris 7	Master	31/10/2003	Cancer biology
PhD in Fundamental basis of oncology, Paris 7	PhD	31/10/2008	Cancer biology
Habilitation to supervise research, Paris 7	HDR	15/03/2015	Cancer biology
Post-doctoral internship, Dana Farber Cancer Institute (Charles Roberts'lab)	-	31/12/2015	Rhabdoid tumors

A. Personal Statement

Franck Bourdeaut is a pediatric oncologist currently working at Institut Curie with two main fields of clinical practice: pediatric neuro-oncology and genetic predisposition to childhood cancer.
In neuro-oncology, Franck Bourdeaut is more particularly involved in pediatric embryonic brain tumors, and presently coordinate the French working sub-group for these entities. He is also the current chair of the European ATRT working group within SIOPe. He has been the French principal investigator of two international Phase I-II trials recruiting patients with SMARCB1-deficient cancers and will be the French principal Investigator of the next European prospective protocol for children with newly diagnosed ATRT. His is also a member of SIOPe Medulloblastoma working group, particularly in charge for France of the development of molecular diagnosis and genetic assesments.
In the field of genetic predisposition, he has co-funded and chaired the French Committee of Oncogenetics for 10 years and is now an elected member of the steering committee of the European group working on predisposition to childhood cancers (SIOPe Host Genome Working Group). He is also a co-funder and member of the pilot committee of the national observatoire for cancer pediatric predispositions syndromes (PREDCAP).

Franck Bourdeaut is also heading a research team dedicated to Smarcb1-deficiency in cancer, and mainly focusing on rhabdoid tumors, within the Translational Research In Pediatric Oncology Lab (INSERM U830 directed by Dr Olivier Delattre). His main interests include i) the development of various mouse models of Smarcb1-deficiency, to elucidate early oncological events and to give access to relevant preclinical tools, and ii) combination of innovative therapies, focusing in particular on immunotherapy and epidrugs.
He has been a recipient of the "Interface INSERM pour hospitaliers" grant, and the SIOP/Arceci innovation Award in 2016.

A. B. Positions, Scientific Appointments, and Honors

Positions and employment

1998-2008 Medical internship in Paris Hospitals, specialist in Paediatrics
2004-2008 Master 2 and PhD internships in Olivier Delattre's lab, Institut Curie
2008-2010 Pediatic onlogist in Nantes University Hospital
2010-present Pediatric onolcogist, Institut Curie
2012-present Head of the Rhabdoid Team and co-PI of the Lab "Translational Research in Pediatric Oncology"

Honors:

Interface INSERM pour Hospitaliers, 2008
Robert Arceci Innovation Award, 2017
Sanofi iAward, 2018

C. Contributions to Science

Publications: 157 (Pubmed)
H index: 38 (Web of Science)
Citations: 4340 (Web of Science)

Selected publications

Enault M, Minard-Colin V, Corradini N, …, **Bourdeaut F.** Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tisue sarcoma Study Group recommendations. Eur J Cancer. 2022 ;161:64-78
PMID: 34929472

Andrianteranagna M, Cyrta J, Masliah-Planchon J, …, **Bourdeaut F.** SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
J Pathol. 2021 ;255:1-15.
PMID: 33999421

Frühwald MC, Nemes K, Boztug H, …, **Bourdeaut F.** Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.
Fam Cancer. 2021;20:305-316.
PMID: 33532948

Leruste A, Chauvin C, Pouponnot C, **Bourdeaut F***, Waterfall JJ*, Piaggio E*. *co-last authors. Immune responses in genomically simple SWI/SNF-deficient cancers. Cancer. 2021 127:172-180.
PMID: 33079397

Ho B, Johann PD, Grabovska Y, De Dieu Andrianteranagna MJ, Yao F, Frühwald M, Hasselblatt M, **Bourdeaut F**, Williamson D*, Huang A*, Kool M*. * co-last authors.
Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.
Neuro Oncol. 2020;22:613-624.
PMID: 31889194

Leruste A, Tosello J, Ramos RN, …, Waterfall JJ*, Piaggio E*, **Bourdeaut F*.** co-last authors. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors.Cancer Cell. 2019 ;36:597-612
PMID: 31708437

Chauvin C, Leruste A, Tauziede-Espariat A, …, **Bourdeaut F.** High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.
Cell Rep. 2017 21:1737-1745.
PMID: 29141209

Geoerger B, **Bourdeaut F**, DuBois SG, …, Chi SN. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017;23:2433-2441.
PMID: 28432176

Richer W, Masliah-Planchon J, Clement N, …, **Bourdeaut F.** Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. Oncotarget. 2017 ;8:34245-34257. PMID: 28427232

Han ZY, Richer W, Fréneaux P, …, **Bourdeaut F.** The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nat Commun. 2016;7:
PMID: 26818002

Calderaro J, Masliah-Planchon J, Richer W, ..., Allory Y*, **Bourdeaut F*.** * co-last authors. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. Eur Urol. 2016;69:1055-61. PMID: 26433572

Rizzo D, Fréneaux P, Brisse H, …, **Bourdeaut F.** SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
Am J Surg Pathol. 2012;36:964-72. PMID: 22614000

Bourdeaut F, Lequin D, Brugières L, …, Delattre O. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res. 2011;17:31-8.PMID: 21208904